Julio G. Martinez-Clark 12/19/24 Julio G. Martinez-Clark 12/19/24

Axoft to Begin Brain Implant Clinical Study, Marking the First Time Bio-Inspired Material is Authorized for Use in Humans

Julio G. Martinez-Clark 12/4/24 Julio G. Martinez-Clark 12/4/24

Protaryx Medical Completes Groundbreaking First-in-Human Trial of Transseptal Puncture Device in Latin America

Sharick Rubio 11/22/24 Sharick Rubio 11/22/24

Paraguay Leads Successful Trials of Second Heart Assist Inc.'s Whisper™ Device

Sharick Rubio 10/30/24 Sharick Rubio 10/30/24

Advanced NanoTherapies Announces Breakthrough in Coronary Disease Treatment with SirPlux™ Duo

Julio G. Martinez-Clark 10/14/20 Julio G. Martinez-Clark 10/14/20

ReGelTec Successfully Treats First Eleven Chronic Low Back Pain Patients with HYDRAFIL™ in Colombia

ReGelTec, Inc., a medical device company developing a percutaneous treatment for chronic low back pain, announced today that eleven patients with degenerative disc disease have been enrolled in the Company’s Early Feasibility Study in Barranquilla, Colombia. The procedures were proctored remotely via Zoom, and all eleven patients were successfully treated with HYDRAFIL™. This patented hydrogel is melted before injection into the nucleus of a degenerated disc via a 17-gauge needle.

Julio G. Martinez-Clark 11/21/19 Julio G. Martinez-Clark 11/21/19

Breakthrough Gene Therapy Clinical Trial is the World's First That Aims to Reverse 20 Years of Aging in Humans

MANHATTAN, Kan., Nov. 21, 2019 /PRNewswire/ -- Libella Gene Therapeutics, LLC ("Libella") announces an institutional review board (IRB)-approved pay-to-play clinical trial in Colombia (South America) using gene therapy that aims to treat and ultimately cure aging. This could lead to Libella offering the world's only treatment to cure and reverse aging by 20 years.